- The CJEU ruled that contributions paid by Boehringer Ingelheim to NEAK for subsidised medicines are considered a reduction in the invoiced price, affirming that NEAK acts as a final consumer in the transaction, which allows Boehringer to adjust its VAT tax base accordingly.
- Boehringer Ingelheim’s contributions were based on the sales of subsidised medicines, and since NEAK did not issue an invoice but requested payment, the court determined that the absence of an invoice does not prevent the adjustment of the tax base if supported by other documentation.
- The ruling reinforces previous judgments, clarifying that the pharmacy must pay VAT on both the NEAK subsidy and the patient’s residual payment, thereby legitimizing the reduction of the tax base due to the contributions made by Boehringer.
Source KPMG
Referring ECJ cases
- Roadtrip through ECJ cases: Focus on ”Discounts”
- C-317/94 – Elida Gibbs Ltd. – Money back and discount coupons – Taxable amount to be adjusted
- C-462/16 – Boehringer Ingelheim Pharma GmbH & Co. KG – Decision – Discounts reduce the VAT value of pharmaceutical supplies
- C-717/19 – Boehringer Ingelheim – Reduction of the taxable amount – Agreement between pharmaceutical company and health insurer
Latest Posts in "Belgium"
- Belgium Launches Next Phase of VAT Chain Modernization Effective May 1, 2026
- Belgium to Launch VAT Provision Account, Replacing Current System from May 2026
- Advocate General: VAT Exemption for Credit Management Applies Only to Current, Not Original, Lender
- Belgian VAT Chain Modernisation: New System and Rules Effective from 1 May 2026
- Key VAT Chain Changes from May 2026: New Accounts, Simplified Management, and Updated Refund Rules














